Sanofi, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sachin Jain from Bank of America Securities maintained a Buy rating on the stock and has a €115.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sachin Jain has given his Buy rating due to a combination of factors including the promising data from Sanofi’s Brivekimig trials and the potential of Tolebrutinib in the SPMS market. The Brivekimig PIIa data showed competitive efficacy in treating Hidradenitis Suppurativa, aligning well with existing market competitors, which suggests a strong position for Sanofi in this therapeutic area.
Furthermore, the upcoming launch of Tolebrutinib for SPMS, with a significant market opportunity and positive PIII study results, adds to the growth prospects. Jain also highlights the potential for an EPS upgrade cycle driven by higher Amvuttra royalties and improved margins, which could further enhance Sanofi’s financial performance. Despite some setbacks in the pipeline, the valuation remains attractive, with a forward EPS growth expectation that supports the Buy recommendation.
In another report released on September 12, Deutsche Bank also maintained a Buy rating on the stock with a €110.00 price target.